A phase I, single-dose, randomized, crossover, relative bioavailability and food-effect study and phase I, single-dose, fixed-sequence, crossover, pH-effect study of belvarafenib (GDC-5573) in healthy subjects
Latest Information Update: 29 Feb 2024
At a glance
- Drugs Belvarafenib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Roche
Most Recent Events
- 26 Feb 2024 Recruitment completion date is 15 May 2023 according to ISRCTN Clinical Trials Registry record
- 17 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 22 Sep 2022 New trial record